ATRION Corp.

Atrion’s approach to product development focuses on meeting market needs with innovative solutions:

For the cardiovascular market, Atrion introduced the MPS^® Myocardial Protection System, providing the surgeon with total flexibility to continually change the mix, temperature, flow rate and precise quantities of medications delivered to the patient during open-heart surgery. The second generation of MPS^®, introduced in 2005 as MPS2^® provides several new functions including cyclic flow capability.
For the ophthalmic market, the company manufactures the LacriCATH^® balloon catheter and the device to inflate it, providing the ophthalmic surgeon with a minimally invasive means of treating blockages in tear ducts.
In fluid delivery, Atrion’s proprietary line of needle-free valves eliminates the use of needles in many routine procedures, thus protecting medical personnel against exposure to infection through accidental needle-sticks.
A key strength of Atrion is its ability to develop customized solutions for small and large customers, and to deliver products to the marketplace quickly and cost-effectively. The company’s focus on creative product design, low-cost manufacturing and exceptional customer service has created a portfolio of well-performing core products and a history of long-standing partnerships with its primary customer base.

Headquartered in Dallas, Texas, Atrion has three facilities — in Texas, Alabama and Florida — housing approximately 400,000 square feet of design, engineering, manufacturing, marketing, and research and development activities.

Atrion’s stock is traded on the Nasdaq Market System under the symbol ATRI.